Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do http://www.frost.com/c/10024/home.do - Healthcare Research Frost & Sullivan Advances in Heart Failure Monitoring and Treatment, Neuromodulation, Regenerative Therapy, GERD, and Cervical Cancer Diagnostics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-14-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-14-00-00 The latest edition of the Medical Devices TOE captures a wide range of innovations in the MedTech space from across the globe. The gamut of innovation profiles include cloud-based monitoring solutions for heart patients, a non-invasive breathalyser for the detection of gastrointestinal diseases, neuromodulation device for the management of migraines, and a home test kit for the detection of cervical cancer, to name a few. This issue is expected to shed light on the myriad areas of research interest in the MedTech space and the diversity in the innovation ecosystem. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Digital health, neuromodulation, woundcare, molecular diagnostics, regenerative medicine Fri, 18 Aug 2017 00:00:00 +0100 Advances in Genetic and Immunotherapy Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-54-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-54-00-00 This edition of the Genetic Technology TOE depicts trends across genetic and immunotherapy. The focus of the TOE is on disease screening and management. The corresponding clinical trials scenario is also depicted along with the industry interactions. In particular, clinical trial analysis and industry interactions around CRISPR/Cas-9 gene editing are highlighted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genetics, disease screening, disease management, T-cell engager cancer immunotherapy, pre-emptive strategies, data security, DNA privacy, single-color digital PCR, enhanced quantitation, circulating DNA, CRISPR/Cas-9 editing, xenotransplantation, gene editing Fri, 18 Aug 2017 00:00:00 +0100 Innovative Solutions for Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-14-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-14-00-00 The latest edition of the Drug Discovery TOE profiles emerging technology platforms, strategic business models and initiatives, breakthrough approvals and trials for drug discovery and development. The role and impact of emerging technology such as artificial intelligence in drug discovery has also been discussed. This TOE issue profiles innovations at the academia research setting, drugs that have received regulatory approval, drug discovery initiatives, and strategies by top pharmaceutical companies. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Orphan designation, IgA nephropathy, induced pluripotent cells, cloud technology, artificial intelligence, public private partnerships, drug discovery, open innovations, fast track initiative, lead optimization, early stage drug discovery, seeding drug discovery initiative Fri, 11 Aug 2017 00:00:00 +0100 Impact of Wearable Technology on the Pharmaceutical Industry http://www.frost.com/prod/servlet/sublib/display-report.do?id=D835-00-20-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D835-00-20-00-00 This edition of Future Tech TechVision Opportunity Engine (TOE) covers the impact of wearable technology on the pharmaceutical industry. Wearables are wireless, sensor integrated devices worn on the body, which can accurately measure body physiological functions and alert users when abnormal parameter levels or fluctuations occur. All these attributes make wearables a favorable technology in the pharmaceutical industry for a variety of applications such as improving drug research and development, streamlining clinical trials, active drug delivery, and patient engagement. This Future Tech TOE also captures market drivers and challenges for wearables in the pharmaceutical industry, technology forecast, and strategic recommendations. The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Wearables, pharmaceutical industry, clinical trials, patient engagement, skin patch, remote monitoring Fri, 11 Aug 2017 00:00:00 +0100 Recent Advances in Genetic Technologies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-53-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-53-00-00 This edition of the Genetic Technology TOE depicts trends across genetic technologies enabling enhanced insights across disease pathogenesis and management. The corresponding clinical validation scenario is depicted along with the industry interactions. A summary of active and completed clinical studies for VM202, a novel gene therapy candidate for ALS, is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Genetic technologies, disease pathogenesis, CRISPR, gene editing, human embryos, gene therapy, amyotrophic lateral sclerosis, gene decoding, bipolar disorder, depressive disorders Fri, 11 Aug 2017 00:00:00 +0100 Global Interventional X-Ray Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD2A-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD2A-01-00-00-00 The study aims to analyze and forecast the Interventional X-ray market in the United States, Europe, and select Asia-Pacific countries for 2016. Research Scope: Market trends (utilization of conventional and emerging clinical applications, growth indicators, factors influencing ROI, critical unmet needs and potential game changing strategies, growth opportunities for fixed interventional X-ray and surgical C-arm systems, emerging clinical application trends, technology trends driving IXR growth, and future prospects); company profiles; competitive structure; market metrics; market share; revenues; and strategies. Regional Scope: United States Europe: Western Europe (Germany, United Kingdom, Italy, France, Spain, Benelux, Scandinavia) and Eastern Europe (Poland, Czech Republic, Hungary, Bulgaria, Romania) Asia-Pacific (Australia, India, Japan, Thailand, Indonesia, Malaysia) Market Segmentation: Fixed interventional X-ray sub-segment (single plane, bi-plane) and Surgical C-arm (Mobile and Mini C-arm), and by the three regions. Market measurements are analyzed for the year 2014-2016 and forecasted up to 202. Revenue and year-on-year growth rates are provided by regions and market segments. Pricing range and growth trends by sub-segment for the base year are discussed. Furthermore, an extensive list of the must-watch manufacturers in the interventional X-ray space in 2016 is provided. Interventional X-ray (IXR) has become ubiquitous in most secondary and tertiary care hospitals as a standard interventional and diagnostic tool for radiology and cardiology. Despite IXR being a matured segment, technological innovation in recent years has resulted in multi-modality integration that blends various clinical applications, which can be carried out using a single suite. With the advent of private hospitals and favorable reimbursements of health insurance, there is more demand for patient safety and high quality technologies, reduced hospitalization, and reduction in overall healthcare costs. Globally, countries are emphasizing safety and outcomes caused by X-ray systems, reduced radiation, seamless workflow, and cost-competitiveness. These factors determine the growth of the interventional X-ray market. Strategies, growth analysis, competitive landscape, and future focus are discussed for vendors (GE Healthcare, Philips Healthcare, Siemens Healthcare, EMD Medical Technologies, Technix, Stephanix S.A, Hologic Inc., Medtronic, BMI Biomedical International s.r.l., EcoRay, Eurocolumbus s.r.l., Intermedical S.r.l., Shimadzu Corporation, Simad S.r.l., and Ziehm Imaging GMBH). The base year for the study is 2016, historic years (2014 and 2015) with 2017 to 2021 as the forecast period. Tue, 8 Aug 2017 00:00:00 +0100 Growth Opportunities in Asia-Pacific Hospital Healthcare Information Technology, 2016 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P982-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P982-01-00-00-00 Hospital health information technology (hospital IT) includes solutions that have a common end goal to improve the quality of in-patient care while reducing cost. For the purpose of this report, the hospital IT market consists of software, solutions, and maintenance services but does not include hardware. The market is segmented into clinical information systems and administrative and financial information systems. Examples of healthcare IT solutions in scope: hospital information systems (HIS) including revenue management, financial management, human resource management, customer relationship management, knowledge management, and supply chain management systems; clinical applications including laboratory information systems (LIS), radiology information systems (RIS), picture archiving and communication systems (PACS); electronic medical records (EMR) and electronic health records (EHR), computerized physician order entry (CPOE), clinical decision support, and patient portals. The hospital IT market in Asia-Pacific (APAC) is the fastest growing amongst all regions globally, expanding at a compound annual growth rate (CAGR) of 9.7% between 2016 and 2021. However, several healthcare industry transformations in the region are creating demand for solution and business model innovation that will truly help care delivery in APAC become more patient-centric and customer-focused. While quality of care is of utmost importance, improving patient satisfaction, creating world-class patient-experience, and enhancing organizational productivity are emerging goals that hospital IT decision makers are aiming for. To granularly understand the challenges, demands, unmet needs, and vendor preferences of hospital IT decision makers in APAC, Frost & Sullivan conducted an online survey that gathered 73 responses from both public and private institutions. Results of the survey were then discussed with local and multinational vendors across the region to understand how they were aligning their growth strategy in response to the observed market dynamics. The combination of demand-side and supply-side research revealed that IT investment in the next five years will be focused on improving health data continuity, utilizing Big Data & Analytics, cloud deployments, and data security systems. Key questions this study will answer: What are the current trends, challenges, and drivers for hospital IT investment in APAC? What will be the most promising Growth Opportunities and key investment areas over the next five years? Are the currently available solutions and vendors adequately meeting market needs? What are the gaps, if any? Are there any early market movers in this direction? What will be the impact and adoption of new technologies? How will these change current industry paradigms and / or bring in new business models? How are expectations from vendors changing and what are some emerging vendor selection criteria? How can APAC hospitals move towards a higher level of patient-centricity? What role do vendors play in this industry shift? Tue, 8 Aug 2017 00:00:00 +0100 Why Healthcare Industry Should Care About Blockchain? http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297776753 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297776753 Blockchain technology provides significant application potential across some of the pressing needs of Healthcare industry. Despite the current euphoria, we need to understand and decode the hype cycle for blockchain technology and its realistic healthcare applications. Fri, 4 Aug 2017 00:00:00 +0100 Recent Advances in Biotherapies http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-52-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-52-00-00 This edition of the Genetic Technology TOE depicts trends across bio-therapies. Monoclonal antibody therapies and siRNA therapies, constitute some examples of the profiled technologies, companies, and university. The corresponding clinical trial scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Monoclonal antibody therapy, plaque psoriasis, siRNA therapy, acute kidney injury, phase 2 study, automated cell processing platform, DNA sunscreen, UV-induced skin damage Fri, 4 Aug 2017 00:00:00 +0100 Innovations in Liquid Biopsy Techniques for Cancer Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CC-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CC-01-00-00-00 This research service encompasses a comprehensive analysis of minimally-invasive and non-invasive biopsy platforms that enable enhanced tumor profiling, treatment monitoring and precision oncology applications. This service primarily focuses on the use of circulating tumor DNA (ctDNA) circulating tumor cells (CTCs) and extracellular vesicles (EVs), derived from bio-fluids such as blood and urine, for molecular analysis across research and healthcare settings. This study also evaluates the technology, clinical, patent, and application landscapes prevalent across liquid biopsy settings, while providing valuable insights across its global technological impact and future perspectives. Tue, 1 Aug 2017 00:00:00 +0100 US Hospital Workforce Management Software Market, Forecast to 2020 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K153-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K153-01-00-00-00 Hospitals often face an intricate balancing act in delivering the right clinical, operational and administrative mix of employees to achieve multiple goals and needs of the enterprise. Connecting all the dots for proactive and on-budget workforce strategic planning is almost impossible to achieve with paper-based systems given the increasing amount and type of data inputs needed. Automation is thus essential for smart, data-driven workforce management. As with other industries undergoing significant disruption and transformation, IT plays an essential role in helping healthcare organizations streamline and optimize operations, including workforce management. Workforce management software solutions help hospitals connect limited human resources with clinical needs based on patient population demographics and patient flow. The objective of this research service is to present a comprehensive analysis of the US Hospital Workforce Management (WFM) Software market. The study describes and defines the market for various types of software applications deployed by US hospitals to manage an array of functions related to labor allocation/human resource management including staffing and scheduling; time and attendance; payroll; patient acuity; benefits administration; and personnel management. The study discusses market megatrends associated with WFM in US hospitals; reviews key factors driving hospitals to deploy and/or upgrade WFM software in response to dynamic industry shifts; outlines key challenges faced by hospitals as they shift from legacy, siloed approaches to WFM software to new data-driven, integrated, cloud-based approaches; reviews key vendors that serve the industry; provides an overall outlook for future business and IT trends for hospital WFM software; and forecasts growth in spending for the hospital WFM software market for the 4-year period of 2017 to 2020. Key Questions This Study Will Answer: What types of products comprise the US hospital WFM software market? What are the key features and functions of these products? Who are the key vendors serving this market? What are the market-shifting megatrends impacting the market for WFM software products in US hospitals? What economic, business, and technological factors are shaping disruption and change? What are the specific drivers and restraints impacting the market for WFM software deployed by US hospitals over the next 4 years? What is the 4-year spend outlook for WFM software deployed by US hospitals? What are the key competitive and growth dynamics that vendors serving the hospital WFM software market need to understand? Mon, 31 Jul 2017 00:00:00 +0100 The Emerging Global Marketplace for Intellectual Property (IP) http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CD-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CD-01-00-00-00 Increased focus to maximize the return from investments in R&D is driving increased participation in the IP marketplace across the value chain. This research service provides an overview of the IP markets value chain and dynamics of the global IP marketplace. The study analyzes existing and emerging business models employed by market participants. The study also covers key issues concerning IP markets and recent developments in this space across the globe. Mon, 31 Jul 2017 00:00:00 +0100 Innovations in Augmented Reality-based Imaging, MRI, Intraoral Imaging, and Endoscopy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-16-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-16-00-00 The latest issue of Medical and Diagnostic Imaging Technologies (MDIT) TechVision Opportunity Engine (TOE) profiles innovations in medical and diagnostic imaging. Some of the profiles covered include augmented reality-based imaging for spinal surgery, NICU-based neonatal MRI unit, miniature camera for intraoral imaging, diagnosis of skeletal abnormalities in fetus in-utero, imaging system for early detection of melanoma, and 360-degree gastrointestinal imaging and endoscope for identifying cause of stroke. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Neonatal MRI, augmented reality, intraoral imaging, endoscopy Fri, 28 Jul 2017 00:00:00 +0100 Advances in Management of Pain, Cancer, and Amyotrophic Lateral Sclerosis http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-51-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-51-00-00 This edition of the Genetic Technology TOE depicts trends across disease management. Extracellular phosphorilation for pain management, biosimilar therapies for cancer, novel antibodies for immunotherapy, and stem cells for rare diseases are profiled. The corresponding clinical trial analysis is depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Disease management, extracellular phosphorylation, pain management, biosimilar therapy, non-squamous non-small cell lung cancer, bispecific antibodies, cancer immunotherapy, mesenchymal stromal cells, amyotrophic lateral sclerosis Fri, 28 Jul 2017 00:00:00 +0100 Technologies Driving Clinical Trial Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CA-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7CA-01-00-00-00 Clinical trials are slow and expensive process. Over the years, especially last year, the number of drugs approved through successful clinical trials has reduced significantly. Due to several clinical trial failures, pharmaceutical companies have suffered significant revenue loss. Based on Frost and Sullivan s research, integration of digital technologies including cloud technology, artificial intelligence, big data, predictive and prescriptive analytics, internet of medical things and mobile technology, into the clinical trial processes can improve the efficiency, fasten the clinical trials processes. Pharmaceutical companies are embracing these digital technologies to improve patient engagement, prevent trial failures, thereby improving the profitability of drug development. This research service will showcase the emerging technologies impacting the clinical trial industry on a global scale, through a detailed strategic assessment of the industry challenges and unmet needs. Integrating of these emerging digital technologies can create further growth opportunities such as increase the chances of trial success through adaptive clinical trials, facilitate remote trials for faster and cost-effective outcomes and increase patient engagement through patient-centric trials. Thu, 27 Jul 2017 00:00:00 +0100 Novel Biomaterials for Medical Applications http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7D9-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7D9-01-00-00-00 This Research Service (RS) offers a strategic perspective on the global emerging industry of biomaterial technologies for various medical applications. This research service is segmented into three chapters, with the first two focusing on analysis of the top trends from both technology and industry perspectives. The third chapter brings out the synergies for partnership initiative within the industry, reviewing the roles and strategies of both existing and emerging participants. Key Questions Answered by this RS: 1. What is the role played by NPD (new product development) and R&D (research and development) initiatives in improving the overall adoption of biomaterials technologies across medical applications? 2. What are the ongoing shifts in the healthcare needs which are largely driving research and development of biomaterials? 3. What are the potential technology-enabled business opportunities that could be explored by existing competitors, and new players entering into the global industry for the biomaterials? 4. Investments in hybrid biomaterials are expected to increase. What are the strategic priorities of existing and new participants in developing the global market? Thu, 27 Jul 2017 00:00:00 +0100 Global Digital Health Sleep Technology Market Companies-to-Action, 2017 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD3F-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD3F-01-00-00-00 The importance of sleep in maintaining general health and wellness is being rapidly recognized by healthcare providers and consumers. Good sleep is associated with increased productivity, vitality, and reduced susceptibility to chronic diseases. The maturing healthcare consumer has started including sleep quality as an important metric to track and is already seeking approaches that can help enhance it. The sleep technology market is flooded with devices, sensors, wearables, and mobile apps that collect sleep data, along with other physiological and activity parameters. Sleep technology consists of a mix of stand-alone, dedicated solutions, as well as technologies integrated with wearables that track multiple parameters. Much like other healthcare wearables markets, the sleep technology market is flooded with small- and medium-sized companies offering modular solutions. Crowdfunding platforms have enabled start-ups to enter with innovative technologies that have the potential to change market paradigms. For the purpose of this research, the entire sleep ecosystem has been explored, including wearables, bed-based sensors, ambient devices, mobile apps, and software, with the goal of understanding how this ecosystem needs to evolve to serve current and future customer needs. The research found 2 major gaps in market offerings: Existing solutions only offer data capture and viewing with basic data analytics. Customers want personalized advice on how they can improve their health and wellness through targeted sleep-enhancing measures. Existing solutions are fragmented, requiring human intervention to integrate data from various channels. A collective ecosystem of sleep technologies is lacking. The future of sleep technologies lies in placing the consumer in the centre and building a network of integrated devices and sensors around him/her that are smart, intuitive, and responsive. Data from sleep devices, sensors, and applications will play a critical role in patient data sets, as part of Big Data needs of providers, payers, and consumers in healthcare. Mobile app experience with sleep technology can bring with it a range of different approaches and data experiences based totally on user preference in the way they choose to interact with their data and insights. Artificial Intelligence systems will be the new partner for consumers in their health. Capabilities such as Amazon Alexa can become an extended part of patient care teams both as an interface and a proactive partner focused on health, wellness, home, diet, and lifestyle suggestions. The key point is for vendors to work more closely and establish partnership models. Key Questions Answered in this Study: What are the growth opportunities in sleep technology? What is the impact of the external industry environment on this market? Which are some unique companies that are introducing new and innovative solutions in the market? How do these companies intend to transform healthcare industry paradigms in the foreseeable future? What is their action plan and potential for growth? What are some key success factors in the sleep technology market? Mon, 24 Jul 2017 00:00:00 +0100 Advances in Vaccines, Energy Harvesting, Smartphones, and Water Treatment http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-50-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-50-00-00 This edition of the Inside R&D TOE depicts recent innovations in healthcare, energy harvesting, and battery-free mobile phone. The TOE also emphasizes on developments in the fields of disposable flu vaccine and water treatment. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Energy harvesting, water treatment, battery-free mobile phone, influenza, flu vaccine Fri, 21 Jul 2017 00:00:00 +0100 Growth Opportunities in the US Prenatal Genetic Testing Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1C4-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1C4-01-00-00-00 Prenatal genetic tests, which are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, and 13, and carrier screens, are gaining momentum in the United States due to enhanced assay outcomes through non-invasive methodologies, increased popularity through social media channels, and the growing number of women choosing to undergo pregnancy at an advanced maternal age. The growth in demand has led to a high level of merger and acquisition activity, apart from numerous collaborations, which in turn has bolstered the product portfolio of several companies in the women s healthcare segment. With this accelerated growth, companies are exploring new avenues to market their products, thereby strategically tying up with IVF clinics, physicians, and OBGYNs. New business models like direct to consumer (DTC) are seeing increased uptake due to ease of use and hassle-free processing. Partnerships with Big Data companies will be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity and sensitivity. Research Scope: The key objectives of this growth opportunity study are to track the changes in the prenatal genetic testing market landscape in the United States from 2016 to 2021. The study aims to identify growth segments and disruptive companies for investment. Further, it provides an in-depth revenue and market share analysis of 4 key segments, namely, NIPT, carrier screening for cystic fibrosis, invasive tests, and miscarriage tests. The study highlights industry challenges, growth drivers and restraints, competitive developments, mergers and acquisitions, and investment opportunities. It also discusses the impact of Protecting Access to Medicare Act (PAMA) and the LDT guidelines issued by the FDA, identifies transforming business models, and makes strategic recommendations to understand market dynamics. The study also covers key trends and growth opportunities, game-changing companies, disruptive technologies, and strategic recommendations. Key questions this study will answer include: What are the long-term growth prospects in the market? What are the other areas of growth outside NIPT? What are the opportunities to explore in carrier screening and miscarriage screening? What are some of the innovative companies to action and to follow? How should you price your tests to remain competitive in the market? Who are the established market participants and what are their strategies to remain competent in this market? Fri, 21 Jul 2017 00:00:00 +0100 Advances in Bone Healing, Wound Care Management, Depression Therapy, Breast Cancer Diagnosis, and Insulin Delivery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-13-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-13-00-00 The latest edition of the Medical Devices TOE profiles innovations in regenerative medicine, digital wound care management, and cancer diagnosis. These innovations span the breadth of the MedTech industry, and have been developed by diverse portfolio of innovators that includes academia, start-ups, and medical device majors from across the globe. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: 3D printing, neuromodulation, wound care, oncology diagnosis Fri, 21 Jul 2017 00:00:00 +0100 Advances in Biopharmaceuticals and Biotechnology http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-50-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-50-00-00 This edition of the Genetic Technology TOE depicts trends across biopharmaceuticals and biotechnology. Diverse innovations in biologics production, drug development, and diagnostics are illustrated. The corresponding clinical validation scenario focused on urinary incontinence is depicted along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Lipid lowering agents, cardiovascular treatment, cellular therapy, niche disease segments, single use bioreactors, biologics production, diagnostic solutions, acute myeloid leukemia Fri, 21 Jul 2017 00:00:00 +0100 US Oncology Diagnostics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K165-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K165-01-00-00-00 Personalized medicine continues to be a driver of new diagnostics to characterize the properties of an individual s cancer. As a result, there is an increased focus on the development of non-invasive liquid biopsy companion diagnostic tests that would aid in choosing the best treatment for an individual. Liquid biopsy has triggered market consolidation, as participants fill the gaps in their technology sets, skill sets, and expertise through the acquisition of specialized laboratories. Amidst the tests for different cancers, in-vitro diagnostic (IVD) tests measuring multiple biomarkers are gaining favor over single-marker tests, because of their improved specificity and sensitivity. When making coverage decisions for new tests, private and government healthcare plans want to see evidence of clinical utility and understand the impact of the tests on patient health outcomes. Important market opportunities that are predicted with high certainty include the clinical integration of clinical sequencing technologies and active participation in strategic partnerships. The falling cost of targeted next-generation sequencing (NGS) will be extremely cost-competitive, with the current single-mutation tests. Additional advantages ensure that clinical sequencing and Big Data will play a key role in cancer patient management. The purpose of this study is to provide an overview of the key technologies, companies, and competitive dynamics of the cancer diagnostics market in the United States. The study covers the following cancer types: breast, ovarian, cervical, colorectal, prostate, and lung. Highlights of the report include: Annual biopsies and projection estimates for all the cancer types (2016 2021) Revenue forecast by technology type (molecular vs non-molecular) and by intended use (screening, prognosis, diagnosis, therapy selection, and therapy monitoring/management) Key trends and growth opportunities Game-changing companies Disruptive technologies and business models Emerging biomarkers and companion diagnostic development landscape Pricing analysis Epidemiology studies for all cancer types (2016 2021) Strategic recommendations and future outlook of cancer market Key questions this study will answer include: Which are the cancer types that hold the highest potential in terms of revenue and growth? What are the tests and technologies used to screen, diagnose, and predict therapy in each of the cancers? Where are the new developments taking place? What does the current and prospective competitive landscape look like? What are the approaches being taken by participants to counter competitive threats? How is the landscape for mergers, acquisitions, and collaborations? What are the emerging biomarker opportunities for breast, prostate, cervical, ovarian, lung, and colorectal cancer for developing new tests? Which are the companies that are driving innovation within each cancer type? Mon, 17 Jul 2017 00:00:00 +0100 Emerging Technology Platforms for Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-13-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-13-00-00 The latest edition of the Drug Discovery TechVision Opportunity Engine (TOE) profiles emerging technology platforms for drug discovery and development. These platforms are diverse and span the spectrum of the life sciences industry, from tissue engineering to companion diagnostics, biomarkers, and cell therapy. This TOE issue strikes a balance between innovations at the academia research setting and technologies that have received regulatory approval and have been commercialized. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Companion diagnostics, tissue engineering, biomarkers, artificial intelligence, cell therapy Fri, 14 Jul 2017 00:00:00 +0100 Advances across the Life Sciences Industry http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4F-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4F-00-00 This edition of the Genetic Technology TOE depicts the current landscape and the new trends across the life sciences industry. Biotechnology innovations in drug discovery, 3D printing, and skin testing are exhibited. The corresponding drug validation scenario is depicted, along with industry interactions. Special focus has been placed on clinical trials for atopic dermatitis, illustrated by phase and region. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biotechnology, drug discovery, 3D printing, skin testing, pharmaceuticals, cosmetics, chemical testing, small molecules, rare diseases, 3D printed organs, cell models, organ transplantation, atopic dermatitis Fri, 14 Jul 2017 00:00:00 +0100 It s Time We See Results: Hospital IT Decision Makers Redefine the Goals & Expectations of IT in APAC http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297722563 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297722563 Asia-Pacific (APAC) is the fastest growing market for hospital information technology (hospital IT) solutions globally, and is expected to generate over $15 billion in revenue by the end of 2021. Thu, 13 Jul 2017 00:00:00 +0100 China Medical Imaging Equipment Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P904-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P904-01-00-00-00 The study aims to analyze and forecast the healthcare imaging market in China (2017 2021). Research scope: Market trends, competitive structure, market metrics, market share, revenues, strategy, and government policies and initiatives. Regional scope: China (excluding Hong Kong) The study includes in-depth analysis of government-driven reforms, covering spending patterns, local manufacturers market situations, group purchasing practices, development of imaging centers, and public healthcare provision, from primary to tertiary care. Products covered include X-ray, ultrasound, CT, MRI, and nuclear imaging (PET/SPECT) systems. CT and MRI are becoming ubiquitous hospital items, with high market penetration and adoption. PET/SPECT remains niche, with slower growth. Various past practices have enabled favoritism across the country. The China government has taken this issue head-on in its development plan, changing regulations and purchasing channels, while also changing the landscape for both local and international brands, with each trying to establish and re-develop during the change. The study also highlights 11 key market themes and offers a glimpse into the future direction of the imaging market in China. It tracks the movement and investment direction by both public and private initiatives in the different regions of China, with emphasis on manufacturers, distributors, and public and private hospitals, as well as the differences between the different hospitals tiers and cities. It explores the historical context for why China is implementing the reforms and assesses the impact towards the strategy for affordable equipment, high-end imaging systems, integrated systems, selection routes on the different types and categories of medical imaging manufacturers, positioning, regulatory directions, and China s approach toward Big Data, highlighting the drivers and priorities in the development platform, procurement, and manufacturing of healthcare imaging systems. This carries on into the models of operation and procurement. Lastly, it looks at what is required for imaging modalities to succeed and grow in the healthcare imaging market of China. This study uses both primary and secondary research to map out the landscape and changes that have affected the healthcare imaging market in China, measuring market share, revenues and growth from 2015 to 2020 (with data from 2014 where 2015 s was not yet available), providing insights for navigating the evolving market. Companies surveyed include Neusoft, Mindray, United Imaging, Wandong Medical Equipment, General Electric, Siemens, Philips, MILabs, IBA Labs, Basda Medical Apparatus, Landwind, Anke, Shanghai United Imaging,Heifei MT Medical, Perling, Mednova, CR Wandong, Aloka, Sonoscape, Besda, Xingaoyi, Liaoning Kampo, Shinva, and Agfa. Healthcare institutions covered include private hospitals, public Tier-I hospitals, Tier-II hospitals, Tier-III hospitals, township healthcare clinics, community healthcare centers, and village healthcare centers. Thu, 13 Jul 2017 00:00:00 +0100 Developments in Cellular Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4E-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4E-00-00 This edition of the Genetic Technology TOE depicts trends across cellular therapies. CAR-T Cell clinical trials and industry interactions are depicted. In particular, a clinical trial overview involving CAR T cells worldwide solid tumors is illustrated. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cellular therapy, CAR-T therapy, inflammatory diseases, test kits, animal testing, natural killer receptor T cells, cancer, allogeneic therapy, oncological conditions Fri, 7 Jul 2017 00:00:00 +0100 Growth Opportunities in APAC Oncology Diagnostics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9A4-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=P9A4-01-00-00-00 There is high growth in the Asia-Pacific (APAC) oncology diagnostics market due to increasing incidence of cancer and the drastic reduction in incidence age owing to a plethora of reasons in the regional market. The major drivers for the APAC cancer diagnostics market are increase in adoption of technology platforms, access to targeted cancer therapeutics and increased demand from patients for affordable and quality care. Furthermore, the global push toward precision medicine has gradually propelled the uptake of innovative platforms such as Next-generation Sequencing (NGS) and liquid biopsy for gradual adoption into mainstream clinical diagnosis. The study examines the APAC oncology diagnostics market, focused on 6 high-prevalence cancers, namely, breast, lung, prostate, colorectal, cervical, and ovarian cancer. The scope of the study includes 10 countries: Japan, China, India, South Korea, Australia, Singapore, Malaysia, Indonesia, Thailand, and Vietnam, with country-level market share and top trends and opportunities driving the oncology diagnostics market. Furthermore, the study identifies the top growth opportunities and market trends that are set to transform the future landscape of oncology diagnostics in APAC. NGS solutions are gradually moving from research to clinical applications, with major regional companies investing in molecular diagnostics as a future growth segment. Luye Pharma s acquisition of Vela Diagnostics, the Genome Asia 100K initiative by Macrogen, multiplexed diagnostic solutions from Seegene Diagnostics, and liquid biopsy tools from Sysmex Inostics are a few examples of trending topics in APAC that will impact the oncology diagnostics market. The market, whose revenue stood at $873.7 million in 2016, is expected to generate a revenue of $1,149.1 million by 2021, growing at a Compound Annual Growth Rate (CAGR) of 5.6%. In addition to the above-mentioned data points, the study also provides information in terms of the key participants across the market by different cancer types as well as some of the new entrants in the market. The following are some key questions that this study will answer. What is the current market scenario for oncology diagnostics in Asia? What are the emerging cancers in Asia with high-growth opportunities in In-vitro Diagnostics (IVD)? What are the regional dynamics currently trending in Asia to combat the rising prominence of cancer, precisely through early screening and surveillance programs? What is the penetration of novel diagnostic solutions across the oncology care continuum? What are the challenges and barriers to address in accelerating the uptake of novel screening or cancer diagnostic tests in Asia? What are the growth opportunities for IVD companies to tap into in the APAC oncology diagnostics market? Thu, 6 Jul 2017 00:00:00 +0100 Future of Thermoelectric Energy Harvesting http://www.frost.com/prod/servlet/sublib/display-report.do?id=D6EB-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D6EB-01-00-00-00 Increased population and pollution are largely contributing to energy crisis. In manufacturing and industrial power plants, a high amount of energy is wasted in the form of heat. Though some countries have restructured their electricity infrastructure with highly expensive processes, the electricity crisis still prevails. This energy and electricity crisis will be a threatening factor for social and economic growth. Energy harvesting is expected to play a major role in managing global energy demands and help in resolving related issues. Thermoelectric Energy Harvesting (TEH) technology comprising thermoelectric generators (TEGs) is a type of energy harvesting technology which is based on Seebeck effect. This aims to leverage thermal sources to generate electrical power and is intended for large-scale and small-scale applications. TEGs have the potential to impact many applications including: Automotive Collision avoidance, regenerative braking, powering auto components Industrial Gas pipelines, geothermal, smart grid cogeneration thermoelectric generators, solar thermal cogeneration Consumer electronics Thermal heat generation from electronic components such as smartphones Home and building automation Smart metering, security system, home entertainment Military and aerospace Military avionics, space telescope cameras, missile testing systems Healthcare Wearable and implantable brain-computer interfaces (BCIs) The technology and innovation report answers the following questions: 1. What is the current status of TEH market? 2. What are the factors that influence development and adoption? 3. What are the innovation hotspots and who are the key developers? 4. What are the patent and funding trends and how does it support development? 5. What are the applications enabled by TEH? 6. What is the market potential for TEH (forecast until 2025)? 7. What are the key needs that drive customer satisfaction? 8. Where do we see growth opportunities? 9. What are the key questions for planning strategic initiatives to drive adoption? Mon, 3 Jul 2017 00:00:00 +0100 Preference to Targeted Therapies and Patient Centric Approaches Drive Transformations in Oncology Drug Delivery Market http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297692601 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297692601 Cancer is the second largest cause of death and is expected to surpass cardiovascular diseases as the leading cause of deaths over the next few years. According to NIH estimates, medical expenditure for cancer in the United States is expected to cross $150 billion by 2020, thereby putting even higher cost pressure on already overburdened US healthcare economy. Fri, 30 Jun 2017 00:00:00 +0100 Recent Advances in Peptide Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4D-00-00 This edition of the Genetic Technology TOE depicts trends across peptide therapeutics. The study covers a variety of disease indications in which peptide therapeutics are being used. A summary of interventional, industry-funded clinical studies using peptide therapeutics for leukemia is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Peptide therapeutics, advanced cancer management, paroxysmal nocturnal hemoglobinuria, glucagon analog, hypoglycemia, type 1 diabetics, synthetic surfactant technology, respiratory distress syndrome, premature infants Fri, 30 Jun 2017 00:00:00 +0100 Advances in Electronics, Batteries, Energy Generation, Water Filtration, and Wound Management http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-4D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-4D-00-00 This edition of the Inside R&D TOE depicts innovations in health care, renewable fuel, and electronics. The TOE also emphasizes on developments in the fields of hydrogen fuel generation, wastewater treatment and smart bandages. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Hydrogen fuel, smart bandage, membrane filtration, fast electronics Fri, 30 Jun 2017 00:00:00 +0100 Growth Opportunities in the Western European Oncology Diagnostics Market, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD29-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD29-01-00-00-00 The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer. The oncology diagnostics market is experiencing consolidation between the major pharma and diagnostic participants who are collaborating to devise and implement disruptive technologies for cancer diagnosis. The research focuses on highlighting some of the major trends occurring in the market alongside these strategic partnerships. Furthermore, emphasis is on the key challenges in the European market in terms of regulations pertaining to companion diagnostics for cancer detection and monitoring. The deliverable outlines some of the major drivers and restraints, impact analysis of major growth opportunities, as well as market engineering measurements. With early detection being a key imperative in oncology diagnosis, the study highlights some of the major technology trends in the market with the application of Artificial Intelligence and Big Data as well as Liquid Biopsy and Next Generation Sequencing, which are expected to reduce the turnaround time for cancer detection, thus speeding up the treatment uptake. Emphasis is given to the emerging biomarkers across the types of cancer, which are expected to aid in faster and easier diagnosis of the disease. Furthermore, analysis is provided for the key participants that are working towards devising new solutions which help to detect these biomarkers, thereby supporting accurate detection and monitoring. In addition to the key participants across the market, new market entrants by different cancer types have been profiled. Some of the key questions answered by the study include: How is the market attractiveness for oncology diagnostics building up over the years? What is the future market potential? How is the adoption of technology affecting the European oncology diagnostic market? Which are the disruptions affecting the value chain equilibrium? How are the new technology trends impacting service providers? How is the changing economic scenario affecting the regional market? Which are the most opportune markets in Europe? What is the application of companion diagnostics on the overall market? How is it expected to impact the market over the next few years? Fri, 30 Jun 2017 00:00:00 +0100 Advances in Molecular Imaging, Neural Imaging, and Multi-modal Image Analysis http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-15-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-15-00-00 The latest issue of Medical and Diagnostic Imaging TOE profiles various innovations from the medical imaging space. These include an advanced visualization platform for multimodal image analysis, Raman spectroscopy probe that detects stray cancer cells, technological refinements for boosting quality of brain scans, an ultra-high definition imaging system for superior endoscopic viewing, precision medicine using imaging biomarkers, and using artificial intelligence for improving diagnostics accuracy. Medical and Diagnostic Imaging TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Multimodal image analysis, Raman spectroscopy, brain scans, precision medicine, biomarkers, artificial intelligence Fri, 30 Jun 2017 00:00:00 +0100 Innovations in Silicon Photonics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7BB-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7BB-01-00-00-00 The silicon photonics (SiP) is an emerging industry with a high level of collaboration between key stakeholders. SiP technology integrates complementary metal-oxide semiconductor (CMOS), three-dimensional (3D) integration, and fiber optic communication technologies. The objective of the SiP technology is to leverage CMOS manufacturing capabilities to fabricate and manufacture photonic devices. The key to enable this is by using silicon as the medium. The innovations in SiP technology have evolved to address the needs of the data transmission market. High bandwidth requirement and high data rate for transmission are two key technical requirements that has driven the advancements in silicon photonics. Key factors that are decreasing the potential for silicon photonics are the inability of the manufacturing process to meet the cost performance demand. Constraints in development in this sector are mainly due to lack of standardized tools and specifications, testing schemes, integration, and packaging techniques. The industry participants are seeking technology development either through investment in research and development (R&D) or through acquisition strategies. Vertical integration is expected to drive the manufacturing and automation activities of large tier participants in the SiP industry. Major participants are expected to wield dominance across the SiP value chain through acquisitions. Optoelectronic product development is expected to be the major area to witness high level of research activities. Key questions answered in the report: 1. What is the current trend in silicon photonics? 2. What is the influence of mega trends? 3. What are the factors driving adoption and development? 4. What are the needs in the market that drive innovation? 5. What are the key R&D focus areas? 6. What is the patent and funding trend and how does it foster innovation? 7. Who are the key innovators? 8. Who are the key competitors and what is the intensity of competition? 9. What are key attractive markets for silicon photonics and where should we invest? 10. What is the impact of key innovations? 11. What is the road ahead for technology development? 12. What are the opportunities for growth? 13. What are the key questions for strategy planning? Thu, 29 Jun 2017 00:00:00 +0100 Microbiome Technologies Energizing Pharma and Life Sciences http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7B3-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D7B3-01-00-00-00 Microbiome science has become a key area of research for biopharmaceutical companies. At present, there are multiple start-ups emerging, which are focusing their resources towards the development of novel therapeutics as well as diagnostic/screening technologies and services. In an era of personalized medicine, the current trajectory of growth witness across the microbiome industry parallels, the growth that took place across genomics. Some of the milestones that have occurred in the microbiome field are the application of next generation screening towards identifying and assessing microbial levels within the human gut. Using these microbial biomarkers, scientists are pushing the boundaries by identifying novel drug targets as well as probiotic or prebiotic products that could aid in balancing the microbial ecosystem within the human body. Wed, 28 Jun 2017 00:00:00 +0100 Does Blockchain Have A Place in Healthcare? http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297683278 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297683278 Blockchain technology is making headlines everywhere. If you have recently attended any tech events it is highly likely that you came out of them having heard just that bit more about it. Everybody is talking about blockchain -- from the President of the United States to the Nigerian Government. Tue, 27 Jun 2017 00:00:00 +0100 Is Doctorless Care the Future of Healthcare? http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297683809 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=297683809 Undoubtedly the current model of sick care is unsustainable due to a number of compelling reasons. The aging population burden tops the list. The United Nations World Population Aging Report paints a grim picture for the future (see Figure 1) from 2025 and beyond, the share of the elderly population Tue, 27 Jun 2017 00:00:00 +0100 Advances in Healthcare, Desalination, and Waste Heat Recovery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-4C-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-4C-00-00 This edition of the Inside R&D TOE depicts developments associated with innovations in healthcare, desalination, and waste heat recovery. The TOE also emphasizes on developments in the fields of stem cells and alternative antibiotics. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Stem cells, sleep therapy, alternative antibiotics, solar desalination Fri, 23 Jun 2017 00:00:00 +0100 Blockchain Technology in Global Healthcare, 2017 2025 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1DB-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K1DB-01-00-00-00 Blockchain technology, with its ubiquitous security infrastructure for seamless health data exchange, holds potential to eliminate the burden and cost of health data reconciliation and facilitate interoperability. Emerging blockchain systems promise to unlock new economic advantages by disintermediating high-cost gatekeepers and automating transactional services across healthcare workflows (e.g., claim adjudication, billing management, RCM, drug supply chain). Increasing pricing pressure to decrease healthcare cost globally and digitization of care delivery models are transitioning the industry toward a much-anticipated personalized treatment paradigm. With these health systems, payers and drug and device manufacturers equally urgently require a secure connected health IT ecosystem to manage healthcare data and promote value-based care. At its core, blockchain offers the potential of a shared platform that decentralizes health data, ensuring access control, authenticity, and integrity of protected health information. Further, the blockchain-based distributed network consensus with cryptography techniques provides an additional layer of trust to minimize cybersecurity threats for healthcare IT systems. This never-before blockchain-based trusted workflow with a single source of truth presents the healthcare industry with radical new possibilities for outcome-based care delivery and reimbursement models. Despite the hype around blockchain, for many people (across different industries), the blockchain concept remains difficult to grasp which makes it one of the most misunderstood technologies of 2017. Blockchain technology may not be the panacea for healthcare industry challenges but it holds the potential to save billions of dollars by optimizing current workflows and the disintermediation of some high-cost gatekeepers. Research Scope The research service analyzes the key trends and developments around blockchain technology and captures the essential building blocks for implementing a healthcare-focused blockchain ecosystem in the next 5 10 years. Differentiating the hype from reality, the study discusses blockchain technology s most potential applications in some of the pressing needs of the healthcare industry such as health data interoperability, cybersecurity, insurance fraud management, and drug supply chain provenance. The study also provides a global flavor around blockchain technology deployment and discusses current adoption trends across major healthcare-focused use cases such as the adoption timeline, growth opportunities, implementation challenges, government and commercial initiatives, select collaboration or deals, and the key companies and consortiums to watch. Finally, the study provides strategic imperatives and recommended business models to foster healthcare-focused blockchain ecosystem partnerships for future implementation on a large scale across healthcare use cases. Key Questions This Study Will Answer What is blockchain technology and what are its implications for the healthcare industry? Who are the key stakeholders in the healthcare blockchain ecosystem? What is the convergence potential for blockchain with emerging healthcare technologies? What are the most promising application areas of blockchain for the healthcare industry? What are the adoption and growth trends for these use cases? Which are the leading companies with healthcare-deployable blockchain solutions? What are the possible business models for blockchain technology deployment in healthcare applications? What are the challenges for implementing blockchain in healthcare? Fri, 23 Jun 2017 00:00:00 +0100 Recent Advances in Cancer Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4C-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-4C-00-00 This edition of the Genetic Technology TOE depicts trends across cancer therapy. Stem cell therapies, check-point inhibitors, and other novel biomarkers are illustrated through the most recent innovations in immuno-oncology. A summary of industry-funded clinical trials for stem cell therapy in blood cancers is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Umbilical cord stem cells, check-point inhibitors, immuno-oncology, immune activation, cancer therapy, immunotherapy, anti-inflammatory functions, predictive biomarkers, precision oncology Fri, 23 Jun 2017 00:00:00 +0100 Growth Opportunities in the Western European IVD Industry, Forecast to 2021 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD00-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MD00-01-00-00-00 Despite global economic and industry challenges, in-vitro diagnostics (IVD) markets continue to grow, mainly due to fast-growing segments like molecular diagnostics, point-of-care testing (POCT), and tissue diagnostics.. A few market dynamics are either positively or negatively affecting certain specific segments in the IVD space; for example, the self-monitoring blood glucose (SMBG) segment's growth in emerging markets is severely dampened by the slowing growth from reimbursement reductions in Western Europe.The broad applicability of POCT, combined with downward pricing trends enabled by microfluidics integration, supports the long-term growth of this segment. The Western European markets continue to drive molecular diagnostics segment growth rather than the emerging Eastern European markets. The recent success of companion diagnostic tests and personalised medicine is driving the uptake of various tests in an aim to save costs, thus opening up an opportunity to expand the test menus in existing installs. Diagnostic testing will continue to move towards process simplicity and decentralisation. IVD market participants are expected to employ a diverse set of strategies rather than rely on comprehensive product portfolios to grow their businesses. Companies are also gaining new market access through acquisitions, and this has intensified competition among tier 1 participants. This study offers comprehensive information on every aspect of the IVD market. It is segmented into 8 subdivisions, namely, immunochemistry, POCT, SMBG, molecular diagnostics, clinical microbiology, haemostasis, hematology, and tissue diagnostics. Discussion on key trends and opportunities and company profile analysis by segment are also provided. In addition, there are dedicated country chapters for the key Western European markets (Germany, France, the United Kingdom, Spain, Italy, Benelux, and Scandinavia) and a snapshot of the regulatory policies awaiting to transform the industry. Fri, 23 Jun 2017 00:00:00 +0100 US Endoscope Repair Solutions Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K183-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K183-01-00-00-00 The study covers current and future market trends, drivers, challenges, and key opportunities in US endoscope repair market. It analyzes the market by application areas such as arthroscopy, ENT endoscopy, GI endoscopy, gynecology, laparoscopy, neurology, pulmonary endoscopy, and urology. The analysis covers both rigid and flexible endoscopes and lists the market opportunities by different end-user categories such as hospitals, day care and ambulatory centers, and stand-alone specialized clinics. Market opportunities are analyzed for 2 sets of endoscope repair market participants original equipment manufacturers (OEMs) and independent service organizations (ISOs). It also provides strategic insights for targeted growth opportunities for each set of participants. The US endoscope repair landscape will see stable pricing levels in the next 5 years, with a mild downward pressure, due to the increasing penetration of ISOs, which are expected to gain market share. However, OEMs will be the dominant participants in terms of both repair volume and value. While the overall endoscope repair market is driven by procedure volume and not as much by repair types and is application-agnostic, GI endoscopy, laparoscopy, and neurology are the target market for flexible endoscopes and are the largest revenue-generating segments. Repair probability is driven by manual cleaning, improper reprocessing using AER, usage frequency, and lifecycle extension. Damage to most endoscopes is driven by improper handling of endoscopes during procedures and not due to regular wear and tear. The study also covers current and forecast market size, as well as current and forecast ISO and OEM penetration in terms of revenue and repair volumes. It offers analysis of budget trends, key influencers, and decision makers in the repair vendor decisions of care providers. Detailed profiles of some key OEMs are provided, with a focus on their endoscope repair capabilities, with an analyst s perspective on OEMs strategic focus on enhancing their repair capabilities. The study also profiles key ISO endoscope repair vendors in the United States. It offers a matrix, comparing the repair capabilities of key OEMs in terms of indicators such as on-site service support, training and education, technology upgrade programs, repair exchange programs, and virtual support capabilities. It also offers comparison of key ISOs in the United States in terms of on-site service support, mobile support, training and education, repair exchange programs, and loaner programs offered by them. Key OEM competitors in the market include Olympus, KARL STORZ, Boston Scientific, Stryker, Fujifilm, B. Braun, Pentax, Smith & Nephew, Conmed Corporation, and Richard Wolf. The major ISOs functioning in the United States include Steris IMS, Mobile Instrument Service and Repair Inc., Prezio Health, Fibertech Medical USA, Total Scope Inc., ERS Repair, and Henry Schein, Inc. Key questions the study will answer include: What are the costs of endoscope repair across common damage areas? What are the different service models operating in the market? What are the future directions? What is the current and forecast market size of the US endoscope repair market in terms of revenue and repair volumes, as well as ISO and OEM penetration rates? Which are the aspects of vendor service that are valued the most by care providers? What are the unmet needs? What are the key growth opportunities for endoscope repair and maintenance vendors for future growth? Wed, 21 Jun 2017 00:00:00 +0100